Hematopoietic and Lymphatic System NeoplasmNCT07306338
Patient Interest in an Integrative Oncology Program at USC Norris Cancer Center: A Single-Institution Needs Assessment
An observational study of Hematopoietic and Lymphatic System Neoplasm and Malignant Solid Neoplasm, run by University of Southern California at 1 site in United States.
Trial summary
This study assesses patient perspectives on the interest in, feasibility, and acceptability of an Integrative Oncology Program for patients at USC NCCC and HC3 Women's Clinic. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- What is being tested?
- Non-Interventional Study
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Dec 2025to 31 Jan 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with solid or hematologic cancer at USC NCCC outpatient clinics or Keck HC3 Women's Health outpatient clinic.
Who may be able to join
- Age ≥ 18 years
- Ability to understand and the willingness to participate in the study.
- English, Spanish, or Chinese speaking
- Patient of USC NCCC Outpatient Clinics or Keck HC3 Women's Health outpatient clinic.
- Diagnosed solid or hematologic Malignancy
Who cannot join
- Unable to provide informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
Xiaoyue M. Guo, 323-409-3422, Xiaoyue.guo@med.usc.edu
Xiaoyue M. Guo
About this study
This study assesses patient perspectives on the interest in, feasibility, and acceptability of an Integrative Oncology Program for patients at USC NCCC and HC3 Women's Clinic.
Read the detailed description
PRIMARY OBJECTIVE:
- To measure patient knowledge, attitudes, and interest in IO program services, identify predictors of willingness to participate or refer, and potential barriers to implementation into existing clinical care workflows.
OUTLINE: This is an observational study.
Patients complete a survey and may participate in a focus group on study.
- Being tested
- Non-Interventional Study
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Non-Interventional StudyOther
Also called Non-Interventional Observational Study, Noninterventional (Observational) Study
Non-interventional study
| Study group | Role | What they receive |
|---|---|---|
| Observational | Patients complete a survey and may participate in a focus group on study. Receives: Other: Non-Interventional Study |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient knowledge about Integrative Oncology (IO) program services
Outcome data will be collected through a survey per the study protocol. National Health Interview Survey (NHIS) - Complementary and Integrative Health (CDC 2024) module, Integrative Medicine Attitude Questionnaire (IMAQ) (Schneider, Meek, and Bell 2003), and Attitudes and Beliefs about Complementary and Alternative Medicines survey (Mao et al. 2012) will be used to quantify current use of and interest in integrative therapies for needs assessment.
Measured: Through study completion, up to 1 year
Patient attitudes about IO program services
Outcome data will be collected through a survey per the study protocol. National Health Interview Survey (NHIS) - Complementary and Integrative Health (CDC 2024) module, Integrative Medicine Attitude Questionnaire (IMAQ) (Schneider, Meek, and Bell 2003), and Attitudes and Beliefs about Complementary and Alternative Medicines survey (Mao et al. 2012) will be used to quantify current use of and interest in integrative therapies for needs assessment.
Measured: Through study completion, up to 1 year
Patient interest in IO program services
Outcome data will be collected through a survey per the study protocol. National Health Interview Survey (NHIS) - Complementary and Integrative Health (CDC 2024) module, Integrative Medicine Attitude Questionnaire (IMAQ) (Schneider, Meek, and Bell 2003), and Attitudes and Beliefs about Complementary and Alternative Medicines survey (Mao et al. 2012) will be used to quantify current use of and interest in integrative therapies for needs assessment.
Measured: Through study completion, up to 1 year
Predictors of willingness to participate or refer
Outcome data will be collected through a survey per the study protocol. Adapted survey items from previously published studies (Larbi et al. 2021; Mao et al. 2014), including willingness to participate and pay will be used to asses this outcome.
Measured: Through study completion, up to 1 year
Potential barriers to implementation
Outcome data will be collected through a survey per the study protocol. National Health Interview Survey (NHIS) - Complementary and Integrative Health (CDC 2024) module, Integrative Medicine Attitude Questionnaire (IMAQ) (Schneider, Meek, and Bell 2003), and Attitudes and Beliefs about Complementary and Alternative Medicines survey (Mao et al. 2012) will be used to quantify current use of and interest in integrative therapies for needs assessment.
Measured: Through study completion, up to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Dec 2025
- Study start15 Dec 2025
- Primary completion31 Jan 2027 (estimated)
- Study completion31 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematopoietic and Lymphatic System NeoplasmStudies of the same condition, open and under way.
- More trials run by University of Southern CaliforniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Southern California
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Xiaoyue M Guo, Principal investigator, University of Southern California
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07306338
- Sponsor's protocol ID
- 0S-25-3
- Other IDs
- NCI-2025-09248, UP-25-00895, 0S-25-3, P30CA014089
- Status last verified
- Mar 2026
- First submitted
- 23 Dec 2025
- Last updated
- 27 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patient Interest in an Integrative Oncology Program at USC Norris Cancer Center: A Single-Institution Needs Assessment
- ClinicalTrials.gov ID
- NCT07306338
- Acronym / sponsor ID
- 0S-25-3
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- University of Southern CaliforniaUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 15 Dec 2025 (actual)
- Primary completion
- 31 Jan 2027 (estimated)
- Study completion
- 31 Jan 2028 (estimated)
- First posted
- 29 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study assesses patient perspectives on the interest in, feasibility, and acceptability of an Integrative Oncology Program for patients at USC NCCC and HC3 Women's Clinic.
Detailed description
PRIMARY OBJECTIVE:
- To measure patient knowledge, attitudes, and interest in IO program services, identify predictors of willingness to participate or refer, and potential barriers to implementation into existing clinical care workflows.
OUTLINE: This is an observational study.
Patients complete a survey and may participate in a focus group on study.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observational | – | Other: Non-Interventional StudyPatients complete a survey and may participate in a focus group on study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with solid or hematologic cancer at USC NCCC outpatient clinics or Keck HC3 Women's Health outpatient clinic.
Key inclusion criteria (5 listed)
- Age ≥ 18 years
- Ability to understand and the willingness to participate in the study.
- English, Spanish, or Chinese speaking
- Patient of USC NCCC Outpatient Clinics or Keck HC3 Women's Health outpatient clinic.
- Diagnosed solid or hematologic Malignancy
Key exclusion criteria (1 listed)
- Unable to provide informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Non-Interventional StudyAlso: Non-Interventional Observational Study, Noninterventional (Observational) StudyNon-interventional study | Other | Observational |
Primary outcome
Patient knowledge about Integrative Oncology (IO) program services
Time frame: Through study completion, up to 1 year
Outcome data will be collected through a survey per the study protocol. National Health Interview Survey (NHIS) - Complementary and Integrative Health (CDC 2024) module, Integrative Medicine Attitude Questionnaire (IMAQ) (Schneider, Meek, and Bell 2003), and Attitudes and Beliefs about Complementary and Alternative Medicines survey (Mao et al. 2012) will be used to quantify current use of and interest in integrative therapies for needs assessment.
Patient attitudes about IO program services
Time frame: Through study completion, up to 1 year
Outcome data will be collected through a survey per the study protocol. National Health Interview Survey (NHIS) - Complementary and Integrative Health (CDC 2024) module, Integrative Medicine Attitude Questionnaire (IMAQ) (Schneider, Meek, and Bell 2003), and Attitudes and Beliefs about Complementary and Alternative Medicines survey (Mao et al. 2012) will be used to quantify current use of and interest in integrative therapies for needs assessment.
Patient interest in IO program services
Time frame: Through study completion, up to 1 year
Outcome data will be collected through a survey per the study protocol. National Health Interview Survey (NHIS) - Complementary and Integrative Health (CDC 2024) module, Integrative Medicine Attitude Questionnaire (IMAQ) (Schneider, Meek, and Bell 2003), and Attitudes and Beliefs about Complementary and Alternative Medicines survey (Mao et al. 2012) will be used to quantify current use of and interest in integrative therapies for needs assessment.
Predictors of willingness to participate or refer
Time frame: Through study completion, up to 1 year
Outcome data will be collected through a survey per the study protocol. Adapted survey items from previously published studies (Larbi et al. 2021; Mao et al. 2014), including willingness to participate and pay will be used to asses this outcome.
Potential barriers to implementation
Time frame: Through study completion, up to 1 year
Outcome data will be collected through a survey per the study protocol. National Health Interview Survey (NHIS) - Complementary and Integrative Health (CDC 2024) module, Integrative Medicine Attitude Questionnaire (IMAQ) (Schneider, Meek, and Bell 2003), and Attitudes and Beliefs about Complementary and Alternative Medicines survey (Mao et al. 2012) will be used to quantify current use of and interest in integrative therapies for needs assessment.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2026.
Related trials for Hematopoietic and Lymphatic System Neoplasm
Recruiting
Tele-HOPE: A Telehealth Pharmacist Opioid Patient Education Pilot Study
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
RecruitingObservational study
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Leukemia, Lymphoma
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Active, not recruitingPhase 2
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
USC / Norris Comprehensive Cancer Center
Los Angeles, United States
Xiaoyue M Guo principal investigator
University of Southern California
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hematopoietic and Lymphatic System Neoplasm and Malignant Solid Neoplasm, run by University of Southern California at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient knowledge about Integrative Oncology (IO) program services (time frame: Through study completion, up to 1 year). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.